Skip to main content
Premium Trial:

Request an Annual Quote

SeraCare's Seraseq Solid Tumor Mutation Mix-II Products

SeraCare Life Sciences has launched its Seraseq Solid Tumor Mutation Mix-II products. This includes eight new products that contain a total of 40 hard-to-sequence variants that  increases the number of insertion-deletion mutations from four to 13. Additionally, the products include two DNA-level structural variants of actionable gene fusions. The company is now providing a single-tube blended reference material format that contains all 40 variants in a tri-level configuration with mutations of 10 percent, seven percent, or four percent allelic frequencies, the company said.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.